Genetic Epidemiology of Sepsis and Septic Shock

 

 Buy Article Permissions and Reprints

ABSTRACT

Sepsis affects more than 750,000 people each year in the United States alone, with a mortality rate of over 35% making it one of the leading causes of death in developed countries. Recent genetic analysis has provided us with several candidate genes, which have become the focus of genetic research in sepsis. The analysis of single nucleotide polymorphisms among various genes, such as those coding for pro- and antiinflammatory mediators, in the septic response has the potential to develop into prediction tools that will permit the clinician to more precisely determine the type of therapy that a particular patient should receive. However, unraveling the genetic variation in sepsis is complicated, and close attention must be paid to study design issues, including the selection of an appropriate study population and sample size and understanding gene-environment interactions. We must anticipate that future implementation of genetic information will lend itself to additional ethical dilemmas when we are faced with allocation of resources.

REFERENCES

• 1 Angus D C, Linde-Zwirble W T, Lidicker J, Clermont G, Carcillo J, Pinsky M R. Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care.  Crit Care Med. 2001;  29 1303-1310
  CrossrefPubMedGoogle Scholar
• 2 Sands K E, Bates D W, Lanken P N et al.. Epidemiology of sepsis syndrome in eight academic medical centers. Academic Medical Center Consortium Sepsis Project Working Group.  JAMA. 1997;  278 234-240
  CrossrefPubMedGoogle Scholar
• 3 Rangel-Frausto M S, Pittet D, Costigan M, Hwang T, Davis C S, Wenzel R P. The natural history of the systemic inflammatory response syndrome (SIRS): a prospective study.  JAMA. 1995;  273 117-123
  CrossrefPubMedGoogle Scholar
• 4 Zeni F, Freeman B, Natanson C. Anti-inflammatory therapies to treat sepsis and septic shock: a reassessment.  Crit Care Med. 1997;  25 1095-1100
  PubMedGoogle Scholar
• 5 Esmon C T. Introduction: are natural anticoagulants candidates for modulating the inflammatory response to endotoxin?.  Blood. 2000;  95 1113-1116
  PubMedGoogle Scholar
• 6 Matthay M A. Severe sepsis: a new treatment with both anticoagulant and antiinflammatory properties [editorial].  N Engl J Med. 2001;  344 759-762
  CrossrefPubMedGoogle Scholar
• 7 Annane D, Sebille V, Charpentier C et al.. Effect of treatment with low doses of hydrocortisone and fludrocortisone on mortality in patients with septic shock.  JAMA. 2002;  288 862-871
  CrossrefPubMedGoogle Scholar
• 8 Bernard G R, Vincent J L, Laterre P F et al.. Efficacy and safety of recombinant human activated protein C for severe sepsis.  N Engl J Med. 2001;  344 699-709
  CrossrefPubMedGoogle Scholar
• 9 Rivers E, Nguyen B, Havstad S et al.. Early goal-directed therapy in the treatment of severe sepsis and septic shock.  N Engl J Med. 2001;  345 1368-1377
  CrossrefPubMedGoogle Scholar
• 10 Sorensen T I, Nielsen G G, Andersen P K, Teasdale T W. Genetic and environmental influences on premature death in adult adoptees.  N Engl J Med. 1988;  318 727-732
  CrossrefPubMedGoogle Scholar
• 11 Collins F S. Shattuck lecture: medical and societal consequences of the Human Genome Project.  N Engl J Med. 1999;  341 28-37
  CrossrefPubMedGoogle Scholar
• 12 Nadel S, Newport M J, Booy R, Levin M. Variation in the tumor necrosis factor-alpha gene promoter region may be associated with death from meningococcal disease.  J Infect Dis. 1996;  174 878-880
  PubMedGoogle Scholar
• 13 Fang X M, Schroder S, Hoeft A, Stuber F. Comparison of two polymorphisms of the interleukin-1 gene family: interleukin-1 receptor antagonist polymorphism contributes to susceptibility to severe sepsis.  Crit Care Med. 1999;  27 1330-1334
  PubMedGoogle Scholar
• 14 Stuber F, Udalova I A, Book M et al.. -308 tumor necrosis factor (TNF) polymorphism is not associated with survival in severe sepsis and is unrelated to lipopolysaccharide inducibility of the human TNF promoter.  J Inflamm. 1995;  46 42-50
  PubMedGoogle Scholar
• 15 Stuber F, Petersen M, Bokelmann F, Schade U. A genomic polymorphism within the tumor necrosis factor locus influences plasma tumor necrosis factor-alpha concentrations and outcome of patients with severe sepsis.  Crit Care Med. 1996;  24 381-384
  PubMedGoogle Scholar
• 16 Mira J P, Cariou A, Grall F et al.. Association of TNF2, a TNF-α promoter polymorphism, with septic shock susceptibility and mortality. A multicenter study.  JAMA. 1999;  282 561-568
  CrossrefPubMedGoogle Scholar
• 17 Cohen J. The immunopathogenesis of sepsis.  Nature. 2002;  420 885-891
  CrossrefPubMedGoogle Scholar
• 17a Cobb J P, Laramie J M, Stormo G D et al.. Sepsis gene expression profiling: murine splenic compared with hepatic responses determined by using complementary DNA microarrays.  Crit Care Med. 2002;  30 2711-2721
  PubMedGoogle Scholar
• 17b Samuel J E, Kiss K, Varghees S. Molecular pathogenesis of Coxiella burnetii in a genomics era.  Ann N Y Acad Sci. 2003;  990 653-663
  PubMedGoogle Scholar
• 17c Hopf H W. Molecular diagnostics of injury and repair responses in critical illness: what is the future of “monitoring” in the intensive care unit?.  Crit Care Med. 2003;  31 S518-S523
  PubMedGoogle Scholar
• 18 Stephens J C, Schneider J A, Tanguay D A et al.. Haplotype variation and linkage disequilibrium in 313 human genes.  Science. 2001;  293 489-493
  CrossrefPubMedGoogle Scholar
• 19 Kumar A, Short J, Parrillo J E. Genetic factors in septic shock.  JAMA. 1999;  282 579-581
  CrossrefPubMedGoogle Scholar
• 20 Kellum J A, Angus D C. Genetic variation and risk of sepsis.  Minerva Anestesiol. 2003;  69 245-253
  PubMedGoogle Scholar
• 21 Lowe P R, Galley H F, Abdel-Fattah A, Webster N R. Influence of interleukin-10 polymorphisms on interleukin-10 expression and survival in critically ill patients.  Crit Care Med. 2003;  31 34-38
  PubMedGoogle Scholar
• 22 Gallagher P M, Lowe G, Fitzgerald T et al.. Association of IL-10 polymorphism with severity of illness in community acquired pneumonia.  Thorax. 2003;  58 154-156
  CrossrefPubMedGoogle Scholar
• 23 Wood K A, Kellum J A, Ferrell R et al.. The IL-10 - 819T polymorphism is associated with increased susceptibility to severe sepsis [abstract].  Crit Care. 2003;  7(Suppl 2) S21
  PubMedGoogle Scholar
• 23a Martin G S, Mannino D M, Eaton S, Moss M. The epidemiology of sepsis in the United States from 1979 through 2000.  N Engl J Med. 2003;  348 1546-1554
  CrossrefPubMedGoogle Scholar
• 24 Holmes C L, Russell J A, Walley K R. Genetic polymorphisms in sepsis and septic shock: role in prognosis and potential for therapy.  Chest. 2003;  124 1103-1115
  CrossrefPubMedGoogle Scholar
• 25 Risch N J. Searching for genetic determinants in the new millennium.  Nature. 2000;  405 847-856
  CrossrefPubMedGoogle Scholar
• 26 Zhang S, Sha Q, Chen H S, Dong J, Jiang R. Transmission/disequilibrium test based on haplotype sharing for tightly linked markers.  Am J Hum Genet. 2003;  73 566-579
  CrossrefPubMedGoogle Scholar
• 27 Iles M M. Linkage and association: the transmission/disequilibrium test for QTLs.  Methods Mol Biol. 2002;  195 101-138
  PubMedGoogle Scholar
• 28 Lee W C. Transmission/disequilibrium test when neither parent is available in some families: a noniterative approach.  J Cancer Epidemiol Prev. 2002;  7 97-103
  PubMedGoogle Scholar
• 29 Devlin B, Roeder K, Wasserman L. Genomic control, a new approach to genetic-based association studies.  Theor Popul Biol. 2001;  60 155-166
  PubMedGoogle Scholar
• 30 Bacanu S A, Devlin B, Roeder K. The power of genomic control.  Am J Hum Genet. 2000;  66 1933-1944
  CrossrefPubMedGoogle Scholar
• 31 Brennan P. Gene-environment interaction and aetiology of cancer: what does it mean and how can we measure it?.  Carcinogenesis. 2002;  23 381-387
  CrossrefPubMedGoogle Scholar
• 32 Lynch M, Walsh B. Genotype X environment interactions. In Genetics and Analysis of Quantitative Ttraits. Sunderland, MA; Sinauer Associates 1998: 657-685
  Google Scholar
• 33 Wood K A, Angus D C. Reducing variation and standardizing practice: the key to better ICU care?.  Curr Opin Crit Care. 2001;  7 281-283
  PubMedGoogle Scholar
• 34 Wood K A, Huang D, Angus D C. Improving clinical trial design in acute lung injury.  Crit Care Med. 2003;  31 S305-S311
  PubMedGoogle Scholar
• 35 Cooper R, Rotimi C, Ataman S et al.. The prevalence of hypertension in seven populations of west African origin.  Am J Public Health. 1997;  87 160-168
  PubMedGoogle Scholar
• 36 Hendrie H C, Ogunniyi A, Hall K S et al.. Incidence of dementia and Alzheimer disease in two communities: Yoruba residing in Ibadan, Nigeria, and African Americans residing in Indianapolis, Indiana.  JAMA. 2001;  285 739-747
  CrossrefPubMedGoogle Scholar
• 37 Cooper R S. Gene-environment interactions and the etiology of common complex disease.  Ann Intern Med. 2003;  139 437-440
  PubMedGoogle Scholar
• 38 Huang Q, Liu D, Majewski P et al.. The plasticity of dendritic cell responses to pathogens and their components.  Science. 2001;  294 870-875
  CrossrefPubMedGoogle Scholar
• 39 Pinsky M R. Genetic testing: costs and access to intensive care unit care.  Crit Care Med. 2003;  31 S411-S415
  PubMedGoogle Scholar

Derek C AngusM.D. M.P.H. 

604 Scaife Hall, Department of Critical Care Medicine, University of Pittsburgh School of Medicine

3550 Terrace St., Pittsburgh, PA 15261

Email: angusdc@ccm.upmc.edu